Liangfeng Han, Ph.D.
Affiliations: | 2009 | Johns Hopkins University, Baltimore, MD |
Area:
Molecular BiologyGoogle:
"Liangfeng Han"Parents
Sign in to add mentor| Kenneth W. Kinzler | grad student | 2009 | Johns Hopkins | |
| (HEYL, a novel negative regulator of TGF-beta pathway in breast cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Han L, Korangath P, Nguyen NK, et al. (2020) HEYL Regulates Neoangiogenesis Through Overexpression in Both Breast Tumor Epithelium and Endothelium. Frontiers in Oncology. 10: 581459 |
| Merino VF, Nguyen N, Jin K, et al. (2016) Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer. Cancer Research |
| Korangath P, Teo WW, Sadik H, et al. (2015) Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3263-73 |
| Mi C, Shi H, Ma J, et al. (2014) Celastrol induces the apoptosis of breast cancer cells and inhibits their invasion via downregulation of MMP-9. Oncology Reports. 32: 2527-32 |
| Han L, Diehl A, Nguyen NK, et al. (2014) The Notch pathway inhibits TGFβ signaling in breast cancer through HEYL-mediated crosstalk. Cancer Research. 74: 6509-18 |
| Ordentlich P, Nguyen N, Jin K, et al. (2012) Abstract P2-09-01: Reactivation of epigenetically silenced retinoic acid receptor-beta for therapy of breast cancer- from molecular mechanism to potential clinical applications Cancer Research. 72 |
| Han L. (2011) A new perspective on estrogen receptor beta in breast cancer progression Cancer Biology and Therapy. 11: 644-646 |
| Lo PK, Lee JS, Liang X, et al. (2010) Epigenetic inactivation of the potential tumor suppressor gene FOXF1 in breast cancer. Cancer Research. 70: 6047-58 |